188752-80-9

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 762-04-9 phosphonic acid diethyl ester 
• 332120-21-5 tetraethyl-4-(trifluoroacetylamino)phenylmethylene-1,1-bisphosphonate 
• 332120-20-4 diethyl-bromo-[4-(trifluoroacetylamino)phenyl]methyl-phosphonate 
• 117758-87-9 diethyl-4-(trifluoroacetylamino)phenylmethyl-phosphonate 
• 20074-79-7 diethyl (4-aminobenzyl)phosphonate 

Downstream Products

• 110466-07-4 <(4-hydroxyphenyl)methylene>diphosphonic acid 
• 925684-77-1 4-(bis(diethylphosphono)methyl)phenyl 7-((4aS,7aS)-1-(tert-butoxycarbonyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylate 
• 925684-78-2 4-(bis(diethylphosphono)methyl)phenyl 7-(4-(tert-butoxycarbonyl)-3-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylate 

Relevant academic research and scientific papers

Preparation of tetraethyl-4-hydroxyphenylmethylene-1,1-bisphosphonate by hydroxy-de-diazoniation of the corresponding diazonium salt of tetraethyl-4-aminophenylmethylene-1,1-bisphosphonate

Bisphosphonates are widely used in diagnosis and therapy of different bone diseases. They are useful agents in osteotic vectorization of antitumor and antiinflammatory drugs because of their potential to accumulate in the inorganic bone matrix hydroxylapa

Bisphosphonate Inhibitors of Mammalian Glycolytic Aldolase

The glycolytic enzyme aldolase is an emerging drug target in diseases such as cancer and protozoan infections which are dependent on a hyperglycolytic phenotype to synthesize adenosine 5′-triphosphate and metabolic precursors for biomass production. To da

Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

The present invention relates to phosphonated fluoroquinolones, antibacterial analogs thereof, and methods of using such compounds. These compounds are useful as antibiotics for prevention and/or the treatment of bone and joint infections, especially for the prevention and/or treatment of osteomyelitis.

Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline phosphatase inhibitors

Calix[4]arenes bearing one or two methylenebisphosphonic acid fragments were prepared via addition of diethylphosphite to the parent calix[4]arene aldehydes. The resulting compounds displayed stronger inhibition of calf intestine alkaline phosphatase than simple methylenebisphosphonic or 4-hydroxyphenyl methylenebisphosphonic acids. The action of these phosphorylated calix[4]arenes is concordant with partial mixed-type inhibition. The inhibition constants Ki and Ki′ for the calix[4]arene bis(methylenebisphosphonic) acid in Tris-HCl buffer at pH 9 are 0.38 μM and 2.8 μM respectively. The replacement of the phosphoric acid moieties on the macrocycle with diethylphosphonates results in a sharp decrease of its inhibitory action. Preorganizing phosphonic acid fragments using a calixarene platform therefore provides a promising approach for the design of efficient alkaline phosphatase inhibitors.